Cargando…

S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS

BACKGROUND: Antipsychotics (APs) are the cornerstone of treatment for severe mental illnesses (SMI) but are associated with significant metabolic side-effects. Individuals who are young, and previously unexposed to AP treatment represent the group that is most vulnerable to AP-metabolic adverse effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa-Dookhan, Kenya, Mahavir Agarwal, Sri, Chintoh, Araba, Mackenzie, Nicole, Casuccio-Treen, Quinn, Remington, Gary, Ward, Kristen, Hahn, Margaret
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session I
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234563/ http://dx.doi.org/10.1093/schbul/sbaa031.155

Ejemplares similares

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY
por: Mahavir Agarwal, Sri, et al.
Publicado: (2020)

Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study
por: Lee, Jiwon, et al.
Publicado: (2023)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021)

S90. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OF WEIGHT GAIN IN PEOPLE WITH SCHIZOPHRENIA: 2019 UPDATE
por: Agarwal, Sri Mahavir, et al.
Publicado: (2020)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023)

Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
por: Stogios, Nicolette, et al.
Publicado: (2021)

S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
por: Bak, Maarten, et al.
Publicado: (2020)

S12. A MACHINE LEARNING FRAMEWORK FOR ROBUST AND RELIABLE PREDICTION OF SHORT- AND LONG-TERM CLINICAL RESPONSE IN INITIALLY ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BASED ON MULTIMODAL NEUROPSYCHIATRIC DATA
por: Ambrosen, Karen S, et al.
Publicado: (2020)

Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis
por: Wu, Sally, et al.
Publicado: (2023)

S77. ROLE OF DOPAMINE AND GLUTAMATE TRANSPORTERS IN GENERATION OF ANTIPSYCHOTIC EFFICACY
por: Kruyer, Anna, et al.
Publicado: (2020)

S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020)

Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia
por: Costa-Dookhan, Kenya A., et al.
Publicado: (2021)

S19. THE ROLE OF ACE AS POSSIBLE BIOMARKER FOR TREATMENT RESISTANCE TO ANTIPSYCHOTICS IN FIRST EPISODE OF PSYCHOSIS
por: Luisa, Longo, et al.
Publicado: (2020)

S3. DOES SWITCHING OR AUGMENTING HELP WITH ANTIPSYCHOTIC-RELATED SEXUAL DYSFUNCTION: SYSTEMATIC REVIEW
por: Allen, Kirsty, et al.
Publicado: (2020)

S210. COMPARATIVE EFFECTIVENESS OF ANTIPSYCHOTICS FOR RISK OF ATTEMPTED OR COMPLETED SUICIDE AMONG PERSONS WITH SCHIZOPHRENIA
por: Taipale, Heidi, et al.
Publicado: (2020)

S195. ROLE OF BOOSTER SESSION TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) FOR PERSISTENT AUDITORY HALLUCINATIONS IN SCHIZOPHRENIA
por: Parlikar, Rujuta, et al.
Publicado: (2020)

The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
por: Raben, Alex T., et al.
Publicado: (2018)

S122. TEN-YEAR FOLLOW-UP AFTER FIRST EPISODE PSYCHOSIS: FOCUSED ON LOW DOSE ANTIPSYCHOTIC MAINTENANCE AND FUNCTIONING
por: Liu, Chen-Chung, et al.
Publicado: (2020)

S182. HISTONE H3 AND H4 POST-TRANSLATIONAL REGULATION IN SCHIZOPHRENIA POSTMORTEM BRAIN: EFFECT OF ANTIPSYCHOTIC TREATMENT
por: Martínez-Peula, Oihane, et al.
Publicado: (2020)

T207. METABOLIC ADVERSE EFFECTS OF OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE ADULT POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bowden, Sylvie, et al.
Publicado: (2020)

S6. SLEEP ENDOPHENOTYPES OF SCHIZOPHRENIA: A HIGH-DENSITY EEG STUDY IN DRUG-NAïVE, FIRST EPISODE PSYCHOSIS PATIENTS
por: Castelnovo, Anna, et al.
Publicado: (2020)

S209. DRUG-NAïVE FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS: PHARMACOLOGICAL TREATMENT PRACTICES IN INPATIENT UNITS IN HUNAN PROVINCE, CHINA
por: Zhu, Mengran, et al.
Publicado: (2020)

S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
por: Blackwood, Clifton, et al.
Publicado: (2020)

Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism
por: Castellani, Laura N., et al.
Publicado: (2019)

Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
por: Stogios, Nicolette, et al.
Publicado: (2023)

S119. A DIMENSIONAL APPROACH TO UNDERSTANDING COST-BENEFIT DECISION-MAKING IN SCHIZOPHRENIA AND DEPRESSION
por: Saperia, Sarah, et al.
Publicado: (2020)

Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls
por: Stogios, Nicolette, et al.
Publicado: (2022)

S177. IMPACT OF NOS1AP AND ITS INTERACTION PARTNERS AT THE GLUTAMATERGIC SYNAPSE ON WORKING MEMORY NETWORKS - AN FMRI IMAGING GENETICS STUDY
por: Raspor, Eva, et al.
Publicado: (2020)

T14. HYPOTHALAMIC-PITUITARY-GONADAL AXIS HORMONES IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE OF PSYCHOSIS AND HEALTHY CONTROLS
por: Teresa Pons-Cabrera, Maria, et al.
Publicado: (2020)

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
por: Singh, Raghunath, et al.
Publicado: (2022)

T154. WHITE MATTER INTEGRITY, DURATION OF UNTREATED PSYCHOSIS, AND ANTIPSYCHOTIC TREATMENT RESPONSE IN MEDICATION-NAïVE FIRST EPISODE PSYCHOSIS PATIENTS
por: Kraguljac, Nina, et al.
Publicado: (2020)

M169. HIPPOCAMPAL GLUTAMATE AND HIPPOCAMPUS SUBFIELD VOLUMES IN ANTIPSYCHOTIC-NAIVE FIRST EPISODE PSYCHOSIS SUBJECTS AND RELATIONSHIPS TO DURATION OF UNTREATED PSYCHOSIS
Publicado: (2020)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

O9.2. ANTIPSYCHOTIC DRUGS IMPAIR BRAIN GLUCOSE SENSING RESULTING IN WHOLE BODY INSULIN RESISTANCE
por: Castellani, Laura, et al.
Publicado: (2020)

M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAïVE SCHIZOPHRENIA PATIENTS
por: Nielsen, Mette, et al.
Publicado: (2020)

S49. THE RELATION BETWEEN PROCESSING SPEED AND USAGE OF MOBILE APPLICATIONS IN PATIENTS WITH SCHIZOPHRENIA
por: Hoşgelen, Emine Ilgın, et al.
Publicado: (2020)

S29. ONE-CARBON METABOLISM AND STRESS IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS RISK SYNDROME: PRELIMINARY DATA
por: Baeza, Inmaculada, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rd5052s983ljj8rtq5gvjcb287